Skip to content Skip to content

Press Releases


Filter Releases
 
INCLINE VILLAGE, Nev., Nov. 3, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2016 including: Total revenues of $53.6 million and $177.8 million for the three and nine months ended September 30, 2016, respectively. GAAP diluted EP...
INCLINE VILLAGE, Nev., Oct. 27, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2016 financial results for the period ended September 30, 2016, on Thursday, November 3, 2016, after market close. PDL's management will host a conference call and webcast that ...
INCLINE VILLAGE, Nev., Aug. 29, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that PDL has received approximately $57.4 million in connection with the termination of PDL's credit agreement with Paradigm Spine, LLC, which included a repayment of the full principal amount outstanding of $54.7 million as ...
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2016 including: Total revenues of $21.0 million and $124.2 million for the three and six months ended June 30, 2016, respectively. GAAP diluted EPS of $0.03...
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that its board of directors has decided to eliminate its quarterly cash dividend. John P. McLaughlin, president and chief executive officer of PDL, stated, "Since 2009, our dividends have been an important element of ou...
INCLINE VILLAGE, Nev., Aug. 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreeme...
INCLINE VILLAGE, Nev., July 28, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at...
INCLINE VILLAGE, Nev., July 6, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has completed an initial equity investment of $75 million in Noden Pharma DAC (Noden), a new privately-held company domiciled in Ireland, and an affiliate.  Noden today announced that it closed its transaction relating to a purchase...
INCLINE VILLAGE, Nev., June 13, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has paid the June 13, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of June 6, 2016, the record date. About PDL BioPharma PDL manages a portfolio of pat...
INCLINE VILLAGE, Nev., June 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:...
INCLINE VILLAGE, Nev., May 24, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sel...
INCLINE VILLAGE, Nev., May 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2016 including: Total revenues of $103.1 million for the first quarter of 2016. Non-GAAP diluted earnings per share (EPS) of $0.52 increased approximately 11 percent versus...
INCLINE VILLAGE, Nev., May 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016.  The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter d...
INCLINE VILLAGE, Nev., April 28, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Easte...
INCLINE VILLAGE, Nev., March 31, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, June 2, 2016, at 10:00 a.m. Pacific Time for all stockholders of record on April 8, 2016. The meeting will take place at the Hyatt Regency Hotel in I...
= add release to Briefcase